Peptide Development Labs
About
  • Overview
  • News
Contact Investor Presentation
Peptide Development Labs
About
  • Overview
  • News
Contact Investor Presentation

Peptide Development Labs Inc.

Terms of Use

Effective date: [Month Day, 2026] · Last updated: [Month Day, 2026]

Contents

  1. 1. Acceptance of these Terms
  2. 2. Purpose of the Site
  3. 3. No medical advice
  4. 4. Investigational products
  5. 5. Do not submit health information
  6. 6. Investor information and no offer of securities
  7. 7. Forward-looking information
  8. 8. Market and third-party data
  9. 9. Intellectual property
  10. 10. Acceptable use
  11. 11. Third-party links
  12. 12. Disclaimer of warranties
  13. 13. Limitation of liability
  14. 14. Indemnity
  15. 15. Governing law
  16. 16. Changes to these Terms
  17. 17. General

1. Acceptance of these Terms

These Terms of Use ("Terms") govern your access to and use of peptidedevelopmentlabs.com (the "Site"), operated by Peptide Development Labs Inc. ("PDL," "we," "us" or "our"). By using the Site, you agree to these Terms and to our Privacy Policy. If you do not agree, please do not use the Site.

2. Purpose of the Site

The Site provides general corporate and investor information about PDL, its platform and its development programs. It is not intended for patients seeking treatment, and nothing on the Site is intended to promote or advertise any drug product to the public.

3. No medical advice

The content on the Site is for general informational purposes only. It is not medical advice and is not a substitute for consultation with a qualified health care professional. Do not use the Site to diagnose or treat any condition. Always seek the advice of your physician with any questions about a medical condition. PDL cannot respond to individual treatment requests. If you are experiencing a medical emergency, call 911 or your local emergency number.

4. Investigational products

VELEMPEX™ is an investigational subcutaneous BPC-157 drug candidate. No marketing authorization has been granted by Health Canada, the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established. Any access to an investigational product, including through Health Canada's Special Access Program, is available only where permitted by law and must be initiated by a treating physician. References to the U.S. Section 503A pathway describe a potential regulatory opportunity that remains subject to final FDA action and applicable federal and state requirements.

5. Do not submit health information

The Site is not designed to receive personal health information. Please do not submit medical records, symptoms, diagnoses or treatment information through the contact form or by email. See our Privacy Policy for how we handle any health information submitted despite this request.

6. Investor information and no offer of securities

Information on the Site is provided for informational purposes and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction. Any offering of securities will be made only in accordance with applicable securities laws and, where required, by means of a prospectus, listing statement or other disclosure document. Nothing on the Site is investment, legal, tax or financial advice.

Investor materials, news releases and presentations are accurate only as of their dates. PDL does not undertake to update them except as required by law. For PDL's continuous disclosure record, please refer to its filings on SEDAR+ at www.sedarplus.ca once available.

7. Forward-looking information

The Site contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws, including statements about PDL's proposed listing, the proposed plan of arrangement, development timelines, regulatory submissions and approvals, manufacturing and licensing milestones, patient access, the U.S. Section 503A pathway, market size and business strategy. Words such as "anticipate," "target," "plan," "expect," "may," "could," "will" and similar expressions identify forward-looking information.

Forward-looking information is based on assumptions management believes are reasonable, but it is subject to known and unknown risks and uncertainties that could cause actual results to differ materially, including regulatory decisions, clinical and manufacturing outcomes, availability of financing, reliance on third-party partners, market conditions, and the other risks described on the Site and in PDL's public disclosure. Readers should not place undue reliance on forward-looking information. PDL disclaims any obligation to update it except as required by law.

8. Market and third-party data

The Site includes market and industry data from third-party sources. PDL believes these sources are reliable but has not independently verified the data and does not guarantee its accuracy or completeness.

9. Intellectual property

The Site and its content, including text, graphics, logos, product renders, images and the VELEMPEX™ and PDL names and marks, are owned by or licensed to PDL and are protected by copyright, trademark and other laws. You may view and print content for your personal, non-commercial use, provided you keep all proprietary notices. You may not otherwise copy, modify, distribute, republish or create derivative works from any content without our prior written consent.

10. Acceptable use

You agree not to:

  • use the Site for any unlawful purpose or in violation of these Terms;
  • attempt to gain unauthorized access to the Site, its servers or any related systems;
  • introduce viruses, malware or other harmful code;
  • use automated tools to scrape, harvest or collect data from the Site;
  • submit false, misleading or impersonating information through the contact form;
  • interfere with the Site's operation or other users' use of it.

11. Third-party links

The Site may link to third-party websites, such as regulators, stock exchanges or news services. We do not control and are not responsible for their content, privacy practices or availability. A link does not imply endorsement.

12. Disclaimer of warranties

The Site and its content are provided "as is" and "as available." To the fullest extent permitted by law, PDL disclaims all warranties, express or implied, including warranties of merchantability, fitness for a particular purpose, accuracy and non-infringement. We do not warrant that the Site will be uninterrupted, error-free or free of harmful components.

13. Limitation of liability

To the fullest extent permitted by law, PDL and its directors, officers, employees, agents and partners will not be liable for any indirect, incidental, special, consequential or punitive damages, or for any loss of profits, data or investment value, arising out of or related to your use of, or inability to use, the Site or its content, including any reliance on it in making an investment or health decision. Some jurisdictions do not allow certain limitations, so some of these limitations may not apply to you.

14. Indemnity

You agree to indemnify and hold harmless PDL and its directors, officers, employees and agents from any claims, losses or expenses (including reasonable legal fees) arising from your breach of these Terms or misuse of the Site.

15. Governing law

These Terms are governed by the laws of the Province of British Columbia and the federal laws of Canada applicable there, without regard to conflict-of-laws principles. You agree to the exclusive jurisdiction of the courts of [Province] for any dispute arising from these Terms or the Site, except where applicable consumer protection law gives you the right to bring proceedings elsewhere.

16. Changes to these Terms

We may update these Terms at any time by posting a revised version on this page with a new "Last updated" date. Your continued use of the Site after changes are posted means you accept the revised Terms.

17. General

If any provision of these Terms is found unenforceable, the remaining provisions will remain in effect. Our failure to enforce any provision is not a waiver. These Terms, together with our Privacy Policy, are the entire agreement between you and PDL regarding the Site.

Building the regulated future of injectable peptide medicine

Trust, speed, and structure - engineered into every peptide we develop.

Investor presentation Contact investor relations
Peptide Development Labs

Peptide Development Labs Inc. · Development-stage pharmaceutical company.

ABOUT
Overview / Why PDL What Is a Peptide The Opportunity Leadership & Governance
CONTACT
info@peptidedev.com +1 (123) 456-7890 Investor relations News releases

VELEMPEX™ is an investigational subcutaneous BPC-157 drug candidate. No marketing authorization has been granted by Health Canada, FDA, EMA or any other regulator. SAP access, if available, is physician-initiated and case-specific. The Company does not promote unsupervised or unauthorized peptide use. © 2026 Peptide Development Labs Inc.

Privacy Policy Terms of Use